

## **Karen Brandt Onel, M.D.**

Hospital for Special Surgery  
Division Pediatric Rheumatology  
535 East 70<sup>th</sup> St.  
New York, NY  
10021  
Office: (212) 606-1302  
Email: onelk@hss.edu

### **ACADEMIC APPOINTMENTS**

1995-1998 Instructor of Pediatrics, Weill Medical College, Cornell University, New York, NY  
1998-2004 Assistant Professor of Pediatrics, Weill Medical College, Cornell University, New York, NY  
2004-2008 Assistant Professor of Pediatrics, The University of Chicago and La Rabida Children's Hospital, Chicago, IL  
2008-2016 Associate Professor of Pediatrics, The University of Chicago, Chicago, IL  
2016- Professor of Clinical Pediatrics, Weill Medical College, Cornell University, New York, NY

### **WORK HISTORY**

1995-2004 Assistant Attending Pediatrician/Assistant Scientist, Hospital for Special Surgery, New York, NY  
1995-2004 Attending Physician, Hospital for Special Surgery, New York, NY  
2004-2016 Attending Physician, University of Chicago Medicine, Chicago, IL  
2004-2008 Attending Physician, La Rabida Children's Hospital, Chicago, IL  
2004-2007 Attending Physician, Advocate Hope Children's Hospital, Oak Lawn, IL  
2007-2016 Attending Physician, Shriner's Hospital for Children, Chicago, IL  
2015-2016 Attending Physician, Edward Hospital, Naperville, IL  
2015-2016 Attending Physician, Elmhurst Hospital, Elmhurst, IL  
2016- Attending Pediatrician, Hospital for Special Surgery, New York, NY

### **LEADERSHIP ROLES**

2003-2004 Director of Pediatrics, Hospital for Special Surgery, New York, NY  
2004-2014 Program Director Pediatric Rheumatology Training Program, The University of Chicago, Chicago, IL  
2011-2016 Section Chief, Pediatric Rheumatology, The University of Chicago, Chicago, IL  
2016- Division Chief, Pediatric Rheumatology, Hospital for Special Surgery, New York, NY

### **ACADEMIC TRAINING**

1981-1985 B.A., History. Yale College, Yale University, New Haven CT  
1985-1989 M.D., Cornell University Medical College, New York, NY  
1989-1992 Residency in Pediatrics, Babies Hospital, Columbia-Presbyterian Medical Center, New York, NY

1992-1995 Clinical Fellowship, Division of Pediatric Rheumatology, Hospital for Special Surgery, New York, NY

### BOARD CERTIFICATION

- 1992 American Board of Pediatrics (recertified 1999, 2008) (Maintenance of Certification Program current)
- 1996 American Board of Pediatrics, Sub-board in Pediatric Rheumatology (recertified 2002) (Maintenance of Certification Program current)

### SCHOLARSHIP

(a) Peer-reviewed publications in the primary literature, exclusive of abstracts:

1. Onel, K., Ashany, D., Nikolic-Zugic, J., Lacy, E., and Elkon K. Expression and function of the murine CD95/ Fas/APO-1 receptor in relation to B cell ontogeny. *European Journal of Immunology* 25:2940-2947, 1995
2. Knipping, E., Krammer, P.H., Onel, K.B., Lehman, T.J.A., Mysler, E., and Elkon, K.B. Levels of soluble APO-1/Fas/CD95 in Systemic Lupus Erythematosus and Juvenile Rheumatoid Arthritis. *Arthritis and Rheumatism* 38:1735-1737, 1995.
3. Lehman, T.J.A. and Onel, K. Intermittent Intravenous Cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus. *J. Peds*, 136:243-247, 2000.
4. Yazici, Y., Onel, K.B., and Sammaritano, L. Neonatal Lupus Erythematosus. *J. Rheum*, 27:807-809, 2000.
5. O'Keefe, K.O., Edelheit, B., Onel, K., Tantawi, M., and Johann-Liang, R. Systemic Lupus Erythematosus in a Pediatric Patient with Congenital AIDS. *Pediatric Infectious Disease Journal*, 20:450-452., 2000.
6. Lehman, T.J., Stiegel, K., and Onel, K.B. Thalidomide therapy for recalcitrant systemic onset juvenile rheumatoid arthritis. *J. Peds*. 140:125-127, 2002.
7. Willis, A.A, Widmann, R.F, Flynn, J.M, Green D.W., and Onel, K.B. Lyme Arthritis Presenting as Acute Septic Arthritis in Children. *J. Peds Ortho*. 23:114-118, 2003.
8. Lehman, T.J.A., Edelheit, B.S., and Onel, K.B. Intravenous methotrexate and cyclophosphamide for refractory lupus nephritis. *Annals of Rheumatic Disease*, 63:321-3, 2004.
9. Moorthy, L.N., Robbins, L., Harrison, M.J., Peterson, M.G.E., Cox, N., Onel, K.B., and Lehman, T.J.A. Quality of life in paediatric lupus. *Lupus*. 13:234-240, 2004.
10. Lehman, T.J.A, Schechter, S.J., Sundel, R.P., Oliveira, S.K., Huttenlocher, A., and Onel, K.B. Thalidomide for Severe Systemic Onset Juvenile Rheumatoid Arthritis: A Multicenter Study. *J. Peds*. 145:856-857, 2004.
11. Moorthy, L.N., Harrison, M.J., Peterson, M., Onel, K.B., and Lehman, T.J.A. Relationship of quality of life and physical function measures with disease activity in children with systemic lupus erythematosus. *Lupus*. 14:280-287, 2005.
12. Adams, A., Onel, K.B., and Lehman, T. Inflammatory Myopathy and Celiac Disease. *Pediatr Rheumatol Online J*. 3: 32-35, 2005.
13. Moorthy, L., Peterson, M., Harrison, M., Onel, K.B., and Lehman, T.J.A. Quality of life in children with systemic lupus erythematosus: a review. *Lupus*. 16:663-9, 2007.
14. Moorthy, L.N., Peterson, M.G., Onel, K.B., and Lehman, T.J.A. Do children with lupus have fewer male siblings? *Lupus*. 17:128-31, 2008.
15. Moorthy, L.N., Peterson, M.G., Baratelli, M., Harrison, M.J., Onel, K.B., Chalom, E.C., Haines, K., Hashkes, P.J., and Lehman, T.J.A. Multicenter validation of a new quality of life measure in pediatric lupus. *Arthritis Rheum*. 57:1165-73, 2007.
16. Suzuki, M., Wiers, K.M., Klein-Gitelman, M.S., Haines, K.A., Olson, J., Onel, K.B., O'Neil, K., Passo, M.H., Singer, N.G., Tucker, L., Ying, J., Devarajan, P., and Brunner, H.I.

- Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis. *Pediatr Nephrol.* 23:403-12., 2008.
17. Moorthy, .LN., Peterson, M.G., Harrison, M.J., Onel, K.B., and Lehman, T.J.A. Physical function assessment tools in pediatric rheumatology. *Pediatr Rheumatol Online J.* Jun 4;6:9, 2008.
  18. Onel, K.B., Huo, D., Hastings, D., Fryer-Biggs, J., Crow, M.K., and Onel, K. Association of the *TP53* Arg72Pro SNP and the *MDM2* SNP309 with Systemic Lupus Erythematosus in Caucasian, African American, and Asian Children and Adults. *Lupus.* 18:61-6, 2009.
  19. Suzuki, M., Wiers, K.M., Brooks, E.B., Gries, K.D., Haines, K., Klein-Gitelman, M.S., Olson, J., Onel, K.B., O'Neil, K., Silverman, E.D., Tucker, L., Ying, J., Devarajan, P., and Brunner, H.I. Initial Validation of a Novel Protein Biomarker Panel for Active Pediatric Lupus Nephritis. *Pediatr Res.* 65:530-536, 2009.
  20. Brunner, H.I., Higgins, G.C., Wiers, K., Lapidus, S.K., Olson, J.C., Onel, K., Punaro, M., Ying, J., Klein-Gitelman, M.S., and Seid, M. Health-related Quality of Life (HRQoL) and its Relationship to Patient Disease Course in Childhood-onset Systemic Lupus Erythematosus (cSLE). *J. Rheum.* 36: 1546-1545, 2009.
  21. Hinze, C.H., Suzuki, M., Klein-Gitelman, M., Passo, M.H., Olson, J., Singer, N.G., Haines, K.A., Onel, K.B., O'Neil, K., Silverman, E.D., Tucker, L., Ying, J., Devarajan, P., and Brunner, H.I. Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity. *Arthritis Rheum.* 60:2772-2881, 2009.
  22. Brunner, H.I., Higgins, G.C., Wiers, K., Lapidus, S.K., Olson, J.C., Onel, K.B., Punaro, M., Ying, J., Klein-Gitelman, M.C., and Giannini, E.H. Prospective Validation of the Provisional Criteria for the Evaluation of Response to Therapy in Childhood-Onset Systemic Lupus Erythematosus. *Arthritis Care Res.* 62:335-344, 2010.
  23. Teshler, M.S., Whitaker, A., Wagner-Weiner, L., and Onel, K.B. Contraception for Adolescents with Lupus. *Pediatr Rheumatol Online J.* Mar 31;8:10, 2010
  24. Brunner, H.I., Klein-Gitelman, M.S., Higgins, G.C., Lapidus, S.K., Levy, D.M., Eberhard A, Singer, N., Olson, J.C., Onel, K.B., Punaro, M., Schanberg, L., von Scheven, E., Ying, J., Giannini, E.H. Toward the development of criteria for global flares in juvenile systemic lupus erythematosus. *Arthritis Care Res.* 62:811-20, 2010.
  25. Brunner, H.I., Higgins, G.C., Klein-Gitelman, M.S., Lapidus, S.K., Olson, J.C., Onel, K.B., Punaro, M., Ying, J., and Giannini, E.H. Minimal clinically important differences of disease activity indices in childhood-onset systemic lupus erythematosus. *Arthritis Care Res.* 62:950-9, 2010.
  26. Mahmood, N.A., Silver, K., Onel, K.B., Ko, M., and Javed, A. Efficacy and Safety of Rituximab in Pediatric Neuromyelitis Optica. *J. Child Neurol.* 26:244-7, 2011.
  27. Brunner, H.I., Mina, R., Pilkington, C., Beresford, M.W., Reiff, A., Levy, D.M., Tucker, L.B., Eberhard, A.B., Ravelli, A., Schanberg, L.E., Saad-Magalhaes, C., Higgins, G.C., Onel, K.B., Singer, N.G., von Scheven, E., Itert, L., Klein-Gitelman, M.S., Punaro, M., Ying, J., and Giannini, E.H. Preliminary criteria for global flares in childhood-onset systemic lupus erythematosus. *Arthritis Care Res.* Sep:63:1213-23, 2011.
  28. Mina, R., Klein-Gitelman, M.S., Ravelli, A., Beresford, M.W., Avcin, T., Espada, G., Eberhard, B.A., Schanberg, L.E., O'Neil, K.M., Silva, C.A., Higgins, G.C., Onel, K.B., Singer, N.G., von Scheven, E., Imundo, L., Nelson, S., Giannini, E.H., and Brunner, H.I. Inactive Disease and Remission in Childhood-onset Systemic Lupus Erythematosus. *Arthritis Care and Res.* May;64:683-93, 2012.
  29. Morgan DeWitt, E., Kimura, Y., Beukelman, T., Nigrovic, P., Onel, K.B., Prahalad, S., Schneider, R., Stoll, M., Angeles-Han, S., Milojevic, D., Schikler, K.N., Vehe, R., Weiss,

- J., Weiss, P., Ilowite, N., and Wallace, C. Consensus Treatment Plans for New-Onset Systemic Juvenile Idiopathic Arthritis. *Arthritis Care Res.* Jul;64:1001-10, 2012.
30. Kimura, Y., Weiss, J., Haroldson, K., Lee, T., Punaro, M., Oliviera, S., Rabinovich, E., Riebschleger, M., Anton, J., Blier, P., Gerloni, V., Haroldson, M,K,E, Onel, K.B., Passo, M., Rennebohm, R., Wallace, C., Woo, P., and Wulffraat, N. Pulmonary Hypertension and Other Potentially Fatal Pulmonary Complications in Systemic Juvenile Idiopathic Arthritis. *Arthritis Care and Res.* May;65:745-52, 2013.
  31. Lovell, D.J., Giannini, E.H., Reiff, A.O., Kimura, Y., Li, S., Hashkes, P.J., Wallace, C.A., Onel, K.B., Foell, D., Wu, R., Biedermann, S., Hamilton, J.D., and Radin, A.R. Long-Term Safety and Efficacy of Riloncept in Patients with Systemic Juvenile Idiopathic Arthritis (sJIA). *Arthritis Rheum.* Sep;65:2486-96, 2013.
  32. Soybilgic, A., Onel, K.B., Utset, T., Alexander, K., and Wagner-Weiner, L. Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years. *Pediatr Rheumatol Online J.* Aug 7;11:29 2013.
  33. Mina, R., Klein-Gitelman, M.S., Nelson, S., Eberhard, B.A., Higgins, G., Singer, N.G., Onel, K.B., Tucker, L., O'Neil, K.M., Punaro, M., Levy, D.M., Haines, K., Martini, A., Ruperto, N., Lovell, D., and Brunner, H.I. Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus. *Ann Rheum Dis.* Feb 73(2):401-6, 2014.
  34. Ringold, S., Weiss, P.F., Colbert, R.A., Dewitt, E.M., Lee, T., Onel, K.B., Prahalad, S., Schneider, R., Shenoi, S., Vehe, R.K., and Kimura, Y. Childhood arthritis and rheumatology research alliance consensus treatment plans for new onset polyarticular juvenile idiopathic arthritis. *Arthritis Care Res.* Jul;66(7):1063-72, 2014.
  35. Soybilgic, A., Teshler, M., Wagner-Weiner, L., and Onel, K.B. A survey of steroid-related osteoporosis diagnosis, prevention and treatment practices of pediatric rheumatologists in North America. *Pediatr Rheumatol.* 12:24. 2014.
  36. Sobel, R.E., Lovell, D.J., Brunner, H.I., Weiss, J.E., Morris, P.W., Gottlieb, B.S., Chalom, E.C., Jung, L.K., Onel, K.B., Petiniot, L., Goldsmith, D.P., Nanda, K., Shishov, M., Abramsky, S., Young, J.P., and Giannini, E.H. Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the phase 4 registry. *Pediatr Rheumatol.* 12:29. 2014.
  37. Mina, R., Klein-Gitelman, M.S., Nelson, S., Eberhard, B.A., Higgins, G., Singer, N.G., Onel, K.B., Tucker, L., O'Neil, K.M., Punaro, M., Levy, D.M., Haines, K., Ying, J., and Brunner, H.I. Effects of obesity on health-related quality of life in juvenile-onset systemic lupus erythematosus. *Lupus.* Feb;24(2):191-7, 2015.
  38. Ringold, S., Hendrickson, A., Abramson, L., Beukelman, T., Blier, P.R., Bohnsack, J., Chalom, E.C., Gewanter, H.L., Gottlieb, B., Hollister, R., Hsu, J., Hudgins, A., Ilowite, N.T., Klein-Gitelman, M., Lindsley, C., LopezBenitez, J.M., Lovell, D.J., Mason, T., Milojevic, D., Moorthy, L.N., Nanda, K., Onel, K.B., Prahalad, S., Rabinovich, C.E., Ray, L., Rouster-Stevens, K., Ruth, N., Shishov, M., Spalding, S., Syed, R., Stoll, M., Vehe, R.K., Weiss, J.E., White, A.J., Wallace, C.A., and Sobel, R.E. A novel method to collect medication adverse events in juvenile arthritis: Results from the Childhood Arthritis and rheumatology research alliance enhanced drug safety surveillance project (EDSSP). *Arthritis Care Res.* Apr; 67(4):529-37, 2015.
  38. Mina, R., Abulaban, K., Klein-Gitelman, M., Eberhard, A., Ardoin, S., Singer, N., Onel, K.B., Tucker, L., O'Neil, K., Wright, T., Brooks, E., Rouster-Stevens, K., Jung, L., Imundo, L., Rovin, B., Witte, D., Ying, J., and Brunner, H.I. Validation of the lupus nephritis clinical indices in childhood-onset systemic lupus erythematosus. *Arthritis Care Res.* Feb;68(2):195-202, 2016

40. Brunner, H.I., Bennett, M., Abulaban, K., Klein-Gitelman, M., O'Neil, K., Tucker, L., Ardoin, S., Rouster-Stevens, K., Onel, K.B., Singer, N., Eberhard, B.A., Jung, L., Imundo, L., Wright, T., Witte, D., Rovin, B., Ying, J., and Devarajan, P. Development of a novel renal activity index of lupus nephritis in children & young adults. *Arthritis Care Res.* Jul;68(7):1003-11, 2016
41. Knight, A., Vickery, M., Muscal, E., Davis, A., Harris, J.G., Soybilgic, A., Onel, K., Schanberg, L.E., Rubinstein, T., Gottlieb, B.S., Mandell, D.S., and von Scheven, E. Identifying Targets for Improving Mental Health Care of Adolescents with Lupus: Perspectives from Pediatric Rheumatology Clinicians in the United States and Canada *J Rheumatol.* Jun;43(6):1136-45, 2016
42. Brunner, H.I., Bennett, M., Abulaban, K., Klein-Gitelman, M., O'Neil, K., Tucker, L., Ardoin, S., Rouster-Stevens, K., Onel, K.B., Singer, N., Eberhard, B.A., Jung, L., Imundo, L., Wright, T., Witte, D., Rovin, B., Ying, J., and Devarajan, P. Development of a novel renal activity index of lupus nephritis in children & young adults. *Arthritis Care Res (Hoboken).* July; 68(7):1003-1011, 2016
43. Horton, D.B., Onel, K.B., Beukelman, T., Ringold, S. Attitudes and approaches for withdrawing drugs for children with clinically inactive nonsystemic JIA: survey of the Childhood Arthritis and Rheumatology Research Alliance. *J. Rheumatol.* March, 44(3):352-360, 2017
44. Kimura, Y., Grevich, S., Beukelman, T., Morgan, E., Nigrovic, P., Mieszkalski, K., Graham, T.B., Ibarra, M., Ilowite, N., Klein-Gitelman, M., Onel, K.B., Prahalad, S., Punaro, M., Ringold, S., Toib, D., Van Mater, H., Weiss, J.E., Weiss, P.F., Schanberg, L.E. Pilot Study Comparing Childhood Arthritis & Rheumatology Research Alliance (CARRA) Systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans. *Peds Rheum.* Apr, 15(1):23.

(b) Invited Reviews:

1. Onel, K. Advances in the medical treatment of juvenile rheumatoid arthritis. *Current Opinion in Pediatrics.* 12:72-75, 2000.
2. Moorthy, L.N. and Onel, K.B. Juvenile idiopathic arthritis: Making the diagnosis. *Journal Musculoskeletal Medicine.* 21:581-588, 2004.
3. Onel, K.B. and Lehman, T.J.A. Review for the Generalist: Evaluation of the adolescent with back pain. *Pediatr Rheumatol Online J.* 3: 109-121, 2005.
4. Moorthy, L.N. and Onel, K.B. Juvenile idiopathic arthritis: Drug treatments. *Journal Musculoskeletal Medicine.* 21:634-639, 2004.
5. Moorthy, L.N., Peterson, M., Onel, K.B., Harrison, M.J., and Lehman, T.J. Quality of life in children with systemic lupus erythematosus. *Curr Rheumatol Rep.* 6:447-52, 2005.
6. Onel, K.B. and Lehman, T.J.A. Back pain in Adolescents. *Pediatric Rheumatology Online J.* 3:109-121, 2005.
7. Onel, K.B. and Spencer, C.H. Health Care Disparities in Children with Rheumatic Diseases. *Pediatric Rheumatology Online J.* 4:101-107, 2006.
6. Onel, K.B. and Onel, K. Anti-TNF Therapy and Cancer Risk in Patients with Autoimmune Disorders. *Arthritis Care and Res.* 62:1024-8, 2010.
9. Teshler, M.S. and Onel, K.B. The Clinical Spectrum of Juvenile Idiopathic Arthritis in a Large Urban Population. *Curr Rheumatol Rep.* 14:116-20, 2012.
10. Onel, K.B. and Onel, K. Tumor Necrosis Factor Inhibitors and Cancer in Juvenile Idiopathic Arthritis: Disentangling the Web. *Arthritis and Rheumatism.* 64:966-9, 2012.
11. Onel, K.B. and Teshler, M. Ethics Forum: Prescribing Teratogenic Medications to Adolescents Can Raise Confidentiality, Ethical Concerns. *The Rheumatologist.* September, 2016

(c) Peer-reviewed works accepted or in press:

None

(d) Book chapters:

1. Onel, K. and Lehman, T.J.A. 2002. Corticosteroids in Adolescence and Childhood. In: Lin AN and Paget S, Eds, Principles of Corticosteroid Therapy Chapman and Hall, New York, Chapter 30, 409-418.
2. Moorthy, L.N., Peterson, M.G.E., Onel, K.B., and Lehman, T.J.A. 2004. Physical function assessment in children with rheumatic diseases. In: Columbus F, Ed, Arthritis Research: Treatment and Management. Nova Science. Hauppauge, NY: Nova Science Publishers; 2005. pp. 127–145.

(e) Other works that are publically available (websites, interviews, publications in the popular press, testimony, computer programs, protocols, reagents, inventions, patents not listed above, etc.):

- |      |   |
|------|---|
| 2008 | “Evaluating Pediatric Back Pain” Rheumatology News<br><a href="http://www.rheumatologynews.com/index.php?id=8821&amp;cHash=071010&amp;tx_ttnews[tt_news]=90137">http://www.rheumatologynews.com/index.php?id=8821&amp;cHash=071010&amp;tx_ttnews[tt_news]=90137</a>   |
| 2010 | “Don’t Get Lost in Translation: Helping Rheumatology Patients with Limited English Skills” The Rheumatologist<br><a href="http://www.the-rheumatologist.org/details/article/867515/Dont_Get_Lost_in_Translation.html">http://www.the-rheumatologist.org/details/article/867515/Dont_Get_Lost_in_Translation.html</a>      |
| 2013 | “Septic Arthritis in Children Ruled Out by New Test” Medscape Medical News<br><a href="http://www.medscape.com/viewarticle/779584">http://www.medscape.com/viewarticle/779584</a>   |
| 2013 | “ACR JIA Recommendations Updated: Use First-Line Anakinra” Medscape Medical News<br><a href="http://www.medscape.com/viewarticle/811699#vp_1">http://www.medscape.com/viewarticle/811699#vp_1</a>   |
| 2015 | “Care and understanding help patient compete in international competition”, Leaders in Care magazine<br><a href="http://edition.pagesuite-professional.co.uk//launch.aspx?eid=0417633a-57e1-46da-9440-c7f0c4082424">http://edition.pagesuite-professional.co.uk//launch.aspx?eid=0417633a-57e1-46da-9440-c7f0c4082424</a> |
| 2015 | “Young boy with autoimmune disease is thriving thanks to care from Comer Children's”, Chicago Parent Magazine<br><a href="http://www.chicagoparent.com/magazines/sponsored-content/2015/comer-autoimmune">http://www.chicagoparent.com/magazines/sponsored-content/2015/comer-autoimmune</a>                              |
| 2017 | “Managing Infection Risk for Kids With Juvenile Arthritis”, Arthritis Foundation: Kids get arthritis, too<br><a href="http://www.kidsgetarthritis.org/living-with-ja/medical-care/health-effects/infection-risk.php">http://www.kidsgetarthritis.org/living-with-ja/medical-care/health-effects/infection-risk.php</a>    |

(f) Clinical trials that are ongoing and unpublished:

1. Lupus Nephritis Clinical Indices Group: enrolling patients, manuscript review  
Status: manuscript in progress
2. CARRA Systemic JIA Consensus Treatment Plan (CTP) Pilot. Role: CTP development, enrolling patients. Status: in progress.
3. Cincinnati Multidisciplinary Clinical Research Center study of TNF blocker withdrawal in Polyarticular JIA. Role: enrolling patients. Status: manuscript in progress

**FUNDING**

Current

CRNT\_REGST01

Duke University/The Arthritis Foundation 09/01/12 – 08/31/15 (Legacy), 7/1/15-Open (New)  
Childhood Arthritis and Rheumatology Research Alliance (CARRA Registry)

The goal of this study is to establish and maintain a clinical database using this minimal data set for at least 60 CARRA sites.

Role: HSS PI

CARRA

Clinical and translational investigation of parenchymal lung disease in sJIA: a planning grant.

The objective of this study is to perform necessary planning for a robust prospective study of parenchymal lung disease in sJIA, with an associated translational arm.

Role: Co-Investigator

Completed at University of Chicago:

A3921104 (9002/0286)

09/01/2016 - Open

Pfizer

Efficacy Study of Tofacitinib In Pediatric JIA Population .

The objectives for this study are to characterize the pharmacokinetics, the pharmacodynamics and the safety of oral Tofacitinib in patients with Polyarticular Course Juvenile Idiopathic Arthritis.

Role: Principal Investigator at the University of Chicago

CNTO 148JIA3003.

06/01/15 – Open

Janssen

A Multicenter, Open-Label Trial of Intravenous Golimumab, a Human Anti-TNF $\alpha$  Antibody, in Pediatric Subjects with Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy, GO VIVA.

The objectives for this study are to characterize the pharmacokinetics, the pharmacodynamics and the safety of intravenous Golimumab in patients with Polyarticular Course Juvenile Idiopathic Arthritis.

Role: Principal Investigator at the University of Chicago

WA28117

10/07/13 – Open

Genentech

A Phase 1b, open-label multicenter study to investigate the pharmacokinetics, and safety of Tocilizumab following subcutaneous administration to patients with polyarticular-course Juvenile Idiopathic Arthritis.

The objectives for this study are to characterize the pharmacokinetics, the pharmacodynamics, and the safety of giving subcutaneous Tocilizumab to patients with Polyarticular-Course Juvenile Idiopathic Arthritis.

Role: Principal Investigator at the University of Chicago

IM101240

04/24/13 – Open

BMS

An Observational Registry of Abatacept in Patients with Juvenile Idiopathic Arthritis

The goal of this project is to establish an international registry with long-term follow-up to characterize and evaluate the safety of abatacept in juvenile idiopathic arthritis.

Role: Principal Investigator at the University of Chicago

CRNT\_REGST01

09/01/12 – 08/31/15 (Legacy),  
7/1/15 – Open (New)

Duke University/The Arthritis Foundation

Childhood Arthritis and Rheumatology Research Alliance (CARRA Registry)

The goal of this study is to establish and maintain a clinical database using this minimal data set for at least 60 CARRA sites.

Role: Principal Investigator at the University of Chicago

WA28118

10/07/13 – Open

Genentech

A phase 1b, open-label, multicenter study to investigate the pharmacokinetics, pharmacodynamics, and safety of Tocilizumab following subcutaneous administration to patients with Systemic Juvenile Idiopathic Arthritis.

The objectives for this study are to characterize the pharmacokinetics, the pharmacodynamics, and the safety of giving subcutaneous Tocilizumab to patients with Systemic Juvenile Idiopathic Arthritis

Role: Principal Investigator at the University of Chicago

NP25737

07/10/12 – Open

Genentech

A phase I pharmacokinetic and safety study of tocilizumab (TCZ) in patients less than 2 years old with active systemic juvenile idiopathic arthritis (sJIA)

The goal of this study is to the PK of TCZ over 12 weeks in patients less than 2 years of age with sJIA.

Role: Principal Investigator at the University of Chicago

P60 AR047784 (Lovell)

09/01/01 – 07/31/13

NIH/NIAMS

Cincinnati Multidisciplinary Clinical Research Center

The Center's chief focus is a greater understanding of the mechanisms of the rheumatic illnesses of childhood and their treatment. Special emphasis is given to cross-disciplinary interactions, and leveraging of resources such that synergism is realized.

Role: Principal Investigator at the University of Chicago

WA18221

10/06/09 – 05/31/13

Roche

A 12-week randomized, double blind, placebo-controlled, parallel group, 2-arm study to evaluate the efficacy and safety of tocilizumab in patients with active systemic juvenile idiopathic arthritis (sJIA); with a 92-week single arm open-label extension to examine the long term use of tocilizumab.

The primary objective of this study is to assess the efficacy and short-term safety of tocilizumab versus placebo in combination with stable ongoing therapy at 12 weeks, with regard to signs



and symptoms in sJIA patients with persistent activity and an inadequate response to NSAIDs and systemic corticosteroids.

Role: Principal Investigator at the University of Chicago

WA19977

10/06/09-05/31/13

Roche

A 24 Week Randomized Double-Blind, Placebo Controlled Withdrawal trial with a 16 week open-label lead-in phase, and 64 week open label follow-up, to evaluate the efficacy and safety of Tocilizumab in Patients with active polyarticular-course juvenile idiopathic arthritis.

The primary objective of this study is to compare the proportion of patients on Tocilizumab versus placebo who develop a JIA ACR30 Flare-up (compared to week 16) by week 40.

Role: Principal Investigator at the University of Chicago

RC2 AR058934

09/31/09 – 08/31/12

NIH/NIAMS

CARRA: Accelerating Toward an Evidence Based Culture in Pediatric Rheumatology

The primary goal of the project is to establish and maintain a clinical database using this minimal data set for 60 CARRA sites in the US, enrolling an average of 325 established and new patients per site into the database, including follow-up visits.

Role: Principal Investigator at the University of Chicago

A3191344

01/01/09 – 06/30/12

Pfizer

SINCERE: Safety in Idiopathic Arthritis: NSAIDS and Celebrex Evaluation Registry: A Prospective Observational Registry of Patients with Juvenile Idiopathic Arthritis (JIA) Treated with NSAIDS

The objective of this multi-center prospective observational Registry is to collect longer-term safety and developmental data on patients treated in routine clinical practice with celecoxib or nsNSAIDs for the signs and symptoms of JIA.

Role: Principal Investigator at the University of Chicago

R01AR051545 (Stevens)

07/13/07 – 07/31/12

NIH/NIAMS

Mechanisms of Tolerance to Renal Maternal Microchimerism

The aim of this study is to test mechanisms by which maternal microchimerism may contribute to chronic inflammation in systemic lupus erythematosus nephritis (SLE-N).

Role: Principal Investigator at the University of Chicago

U01 AR005909 (Brunner)

08/08/10 – 05/31/12

NIH/NIAMS

Towards Measures of Lupus Nephritis Activity and Damage for Children

The objective of this application is to make accurate validated measures of LN activity and damage for cSLE available to clinicians and researchers.

Role: Principal Investigator at the University of Chicago

## **HONORS, PRIZES, AND AWARDS**

Undergraduate

Magna Cum Laude Graduate  
Honors in History

Medical School

David P. Barr Fellowship, 1986

Alpha Omega Alpha, 1988  
Janet M. Glasgow Memorial Achievement Citation, 1989  
Mitchell Spivak Memorial Prize in Pediatrics, 1989

Fellowship ACR Senior Rheumatology Scholar Award, 1994  
ACR Pediatric Rheumatology Research Award, 1994

Current Chicago Arthritis Walk Medical Honoree, 2013  
Amgen Pediatric Rheumatology Visiting Professorship, 2014, 2015  
Chicago's Top Doctors, 2012, 2014, 2016  
America's Top Doctors, Castle Connolly, 2014-2016

### **INVITED SPEAKING**

1998-2012 Annual presentation: "Pediatric Rheumatology for the Internist",  
New York Rheumatism Association Annual Board Review  
Course, New York, NY

2006 "Lupus, 2006 and Beyond", Hope Children's Hospital Seminar  
for Physicians, Oak Lawn, IL

2006 "Recent Advances in JIA" Updates in Pediatric Rheumatology,  
Robert Wood Johnson Medical Center, New Brunswick, NJ

2008 Pediatric Rheumatology for the Pediatric Board Exam, Hope  
Children's Hospital Board Review Course, Oak Lawn, IL,

2011 "2011 Update in Juvenile Idiopathic Arthritis: Where Are We?"  
Pediatric Grand Rounds, Resurrection Medical Center,  
Chicago, IL

2011 "2011 Update in Juvenile Idiopathic Arthritis: Where Are We?"  
Pediatric Grand Rounds, Edwards Hospital, Naperville, IL

2012 "Systemic Juvenile Idiopathic arthritis and your child." Juvenile  
Arthritis Conference, St. Louis, MO

2014 "2014 Update in Juvenile Idiopathic Arthritis: Where Are We?"  
Pediatric Grand Rounds, University of Miami, Miami, FL

2014 "2014 Update in Juvenile Idiopathic Arthritis: Where Are We?"  
Pediatric Grand Rounds, William Beaumont Hospital, Royal  
Oak, MI

2014 "2014 Update in Juvenile Idiopathic Arthritis: Where Are We?"  
Rheumatology Grand Rounds, Rush University Medical Center,  
Chicago, IL

2015 "2015 Update in Juvenile Idiopathic Arthritis: Where Are We?"  
Pediatric Grand Rounds, Children's Hospital of Illinois, Peoria,  
IL

2015 "2015 Update in Juvenile Idiopathic Arthritis: Where Are We?"  
Pediatric Grand Rounds, Nationwide Children's Hospital,  
Columbus, OH

2015 "How to get what you need from your doctors and nurses."  
Improving Your Health Experience," Lupus Foundation of  
America (speaker and course organizer), Chicago, IL

2015 "Inactive Disease in Systematic Juvenile Idiopathic Arthritis."  
CARRA Annual Scientific Meeting, Austin, TX

2016 HSS

2017 "My Child's Wellness." Arthritis Foundation of New York, NY

- 2017 “JIA—25 years in the making.” Pediatric Rheumatology Grand Rounds, Children’s Hospital at Montefiore, Bronx, NY
- 2017 “From JRA to JIA-a Tale of Two Cities.” Pediatrics Grand Rounds, New York Presbyterian Hospital, New York, NY
- 2017 “JIA—Are We There Yet?”, Rheumatology Grand Rounds, Hospital for Special Surgery, New York, NY

Continuing medical education:

- 2000-2012 “Brief Overview of the Pediatric Rheumatic Diseases.” New York Rheumatism Association Board Review Course, New York, NY, Sept.
- 2015 “Head, Shoulders, Knees and Toes,” Shriner’s Children’s Hospital, Chicago, IL, March 7.
- 2015 “Crash: Injury Prevention and the Child.” Department of Pediatrics, The University of Chicago, Chicago, IL (Course Organizer), May 15.
- 2015 “2016 Updates in Juvenile Idiopathic Arthritis: Where Are We?” Edward Hospital, Chicago, IL, Dec 3.

**INVITED, ELECTED, OR APPOINTED EXTRAMURAL SERVICE**

American College of Rheumatology

- 2011, 2012 Annual Meeting Abstract Reviewer
- 2012 American College of Rheumatology Annual Meeting Moderator: Neuropsychiatric Lupus in Children and Adults Moderator: Childhood SLE and Other Vasculitides
- 2012-2014 Annual Meeting Planning Committee
- 2013 American College of Rheumatology Annual Meeting Moderator: Kawasaki Disease: Putting Out the Fire
- 2014 PRYSM Abstract Review Committee
- 2015 Amigo Mentoring Bootcamp panelist
- 2015-2018 American College of Rheumatology Committee on Ethics and Conflict of Interest
- 2016 Moderator: Is Your Patient Googling You? How the Sunshine Act and Public Websites Allow Patients to Learn
- 2017 PRYSM Abstract Review Committee

Childhood Arthritis & Rheumatology Research Alliance (CARRA)

- 2012-2013 Midwest Representative to the Arthritis Foundation
- 2012-2015 Elections Committee, 2012-2015
- 2011-current New onset Systemic JIA Consensus Treatment Plan Development Committee
- 2013-current New onset Polyarticular JIA Consensus Treatment Plan Development Committee
- 2015-2017 Annual Meeting Systemic JIA session Organizing Committee
- 2015-2017 CARRA Finance Committee
- 2017 CARRA Ethics Committee

Pediatric Rheumatology Collaborative Study Group (PRCSG)

2015-2017 Advisory Council

Arthritis Foundation

2015-2016 Leadership Board Member (Chicago)  
2015-2016 Juvenile Arthritis Committee (Chicago)  
2017- Juvenile Arthritis Committee (New York)

## **SERVICE**

Hospital for Special Surgery

2016- Academic Leadership Council  
2017- Institutional Review Board Scientific Voting Member  
2017- Clinical Operations Committee  
2017- Education & Social Services CRP  
2017- Child Protection Committee

The University of Chicago

### Committee membership:

2010-2014 Institutional Review Board  
2011-2014 The University of Chicago pediatric representative to the Autoimmune Centers of Excellence  
2012-2016 The University of Chicago Faculty Practice Plan Committee  
2014-2016 The University of Chicago Medicine CME Faculty Strategy Group  
2014 Search Committee for Section Chief Pediatric Cardiology  
2014-2015 Search Committee for Pediatric Department Chair  
2015-2016 Search Committee for Section Chief Pediatric Neurology  
2015-2016 Member, Pediatric Committee on Appointments and Promotion

### Leadership:

2004-2014 Director, Pediatric Rheumatology Training Program  
2014 Co-Leader, Children's Ops/Facilities Strategy Workgroup  
2014-2016 Vice-Chair Committee C, BSD Institutional Review Board  
2014-2016 Director of Pediatric Continuing Medical Education  
2015-2016 Co-Chair Pediatric Women's Committee

## **EDITORIAL RESPONSIBILITIES**

Manuscript and Grant Reviewer for:

Seminars in Arthritis and Rheumatism (Associate Editor)  
Arthritis Foundation  
Arthritis and Rheumatism  
Pediatric Rheumatology (Editorial Board)  
LUPUS  
Arthritis Care and Research

## **PROFESSIONAL SOCIETIES**

American College of Rheumatology (ACR)  
Childhood Arthritis & Rheumatology Research Alliance (CARRA)  
Pediatric Rheumatology Collaborative Study Group (PRCSG)